OMB APPROVAL
--------------------------
OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response......11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
SIRNA THERAPEUTICS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.01 PAR VALUE
--------------------------------------------------------------------------------
(Title of Class of Securities)
829669100
--------------------------------------------------------------------------------
(CUSIP Number)
August 15, 2003
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
PERSONS WHO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE
NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL
NUMBER.
SEC 1745 (12-02)
CUSIP NO. 829669100 13G Page 2 of 5 Pages
--------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Eli Lilly and Company
35-0470950
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
-----------------------------------------------------------------
(b) [ ]
-----------------------------------------------------------------
Not Applicable
--------------------------------------------------------------------------------
3. SEC Use Only
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization
Indiana
--------------------------------------------------------------------------------
Number of 5. Sole Voting Power
Shares 0
-----------------------------------------------------
Beneficially 6. Shared Voting Power
Owned by 0
-----------------------------------------------------
Each 7. Sole Dispositive Power
Reporting 0
-----------------------------------------------------
Person With: 8. Shared Dispositive Power
0
--------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
0
--------------------------------------------------------------------------------
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
Not Applicable
--------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9)
0%
--------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
CO
--------------------------------------------------------------------------------
CUSIP NO. 829669100 13G Page 3 of 5 Pages
Item 1(a). Name of Issuer:
Sirna Therapeutics, Inc.
Item 1(b). Address of Issuer's Principal
Executive Offices:
2950 Wilderness Place
Boulder, Colorado 80301
Item 2(a). Name of Person Filing:
Eli Lilly and Company
Item 2(b). Address of Principal Business
Office or, if None, Residence:
Lilly Corporate Center
Indianapolis, IN 46285
Item 2(c). Citizenship:
Indiana
Item 2(d). Title of Class of Securities:
Common Stock, $.01 Par Value
Item 2(e). CUSIP Number:
829669100
Item 3. If this statement is filed pursuant to Rule
13d-1(b), or 13d-2(b) or (c), check whether the
person filing is a:
(a)-(j) Not applicable
If this statement is filed pursuant to Rule 13d-1(c),
check this box. [X]
CUSIP NO. 829669100 13G Page 4 of 5 Pages
Item 4. Ownership.
(a) Amount Beneficially Owned:
0
(b) Percent of Class:
0%
(c) Number of shares as to which the person has:
Sole voting power 0
Shared voting power 0
Sole dispositive power 0
Shared dispositive power 0
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact
that as of the date hereof the reporting person has
ceased to be the beneficial owner of more than five
percent of the class of securities, check the
following [X].
Item 6. Ownership of More Than Five Percent on Behalf of
Another Person.
Not applicable
Item 7. Identification and Classification of the Subsidiary
which Acquired the Security Being Reported on by
the Parent Holding Company.
Not applicable
Item 8. Identification and Classification of Members of
the Group.
Not applicable
Item 9. Notice of Dissolution of Group.
Not applicable
CUSIP NO. 829669100 13G Page 5 of 5 Pages
Item 10. Certifications.
By signing below, I certify that, to the best of my
knowledge and belief, the securities referred to
above were not acquired and are not held for the
purpose of or with the effect of changing or
influencing control of the issuer of the securities
and were not acquired and are not held in connection
with or as a participant in any transaction having
that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
ELI LILLY AND COMPANY
By: /s/ Charles E. Golden
----------------------------
Charles E. Golden
Executive Vice President
and Chief Financial Officer
Date: February 13, 2004